Patents Assigned to Genentech
  • Compositions and methods for enhancing apoptosis
    Publication number: 20090148921
    Abstract: The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 14, 2006
    Publication date: June 11, 2009
    Applicant: Genentech, Inc.
    Inventors: Kurt Deshayes, Wayne Fairbrother, John Flygare, Matthew C. Franklin, Saloumeh Fischer, Domagoj Vucic
  • ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY
    Publication number: 20090148435
    Abstract: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.
    Type: Application
    Filed: October 29, 2008
    Publication date: June 11, 2009
    Applicant: Genentech, Inc.
    Inventors: Benedicte Andree Lebreton, Deborah Ann O'Connor, Aurelia Safta, Mandakini Sharma
  • Promotion of axonal regeneration
    Patent number: 7544659
    Abstract: The present invention concerns a method of promoting axonal regeneration. In particular, the invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with the loss, loss of function or dysfunction of nerve cells, in particular thalamic nerve cells, by administering a polypeptide having a high degree of sequence identity with a native sequence Netrin G1 (NGL-1) or an agonist thereof.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: June 9, 2009
    Assignee: Genentech, Inc.
    Inventors: John (Chia-Yang) Lin, Arnon Rosenthal
  • Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
    Patent number: 7544482
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: June 9, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J Godowski, J Christopher Grimaldi, Austin L Gurney, William I Wood
  • SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
    Publication number: 20090142786
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: February 2, 2009
    Publication date: June 4, 2009
    Applicant: GENENTECH, INC.
    Inventors: KEVIN P. BAKER, MAUREEN BERESINI, LAURA DEFORGE, LUC DESNOYERS, ELLEN FILVAROFF, WEI-QIANG GAO, MARY E. GERRITSEN, AUDREY GODDARD, PAUL J. GODOWSKI, AUSTIN L. GURNEY, STEVEN SHERWOOD, VICTORIA SMITH, TIMOTHY A. STEWART, DANIEL TUMAS, COLIN K. WATANABE, WILLIAM I. WOOD, ZEMIN ZHANG
  • Anti-VEGF antibodies
    Publication number: 20090142343
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 4, 2009
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
    Publication number: 20090142259
    Abstract: The present invention is directed to methods of diagnosing and treating, as well as articles of manufacture useful for diagnosing and treating, bladder and/or urinary tract tumor in mammals.
    Type: Application
    Filed: May 9, 2007
    Publication date: June 4, 2009
    Applicant: Genentech, Inc.
    Inventors: Wei-Qiang Gao, Bu-er Wang
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090142348
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO844, PRO1131 or PRO5992 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: May 21, 2007
    Publication date: June 4, 2009
    Applicants: GENENTECH, INC., LEXICON PHARMACEUTICALS, INC.
    Inventors: Frederic de Sauvage, Ellen Filvaroff, Jagath Reddy Junutula, Bobby Joe Payne, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel
  • THERAPY OF OCULAR DISORDERS
    Publication number: 20090136492
    Abstract: The present application describes therapy of ocular disorders using antagonists, such as antibodies, that bind to CD20.
    Type: Application
    Filed: October 26, 2007
    Publication date: May 28, 2009
    Applicant: Genentech, Inc.
    Inventor: PAUL G. BRUNETTA
  • Apo-2 ligand variants and uses thereof
    Publication number: 20090137476
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 28, 2009
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • Compositions and Methods for the Diagnosis and Treatment of Tumor
    Publication number: 20090136928
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 28, 2009
    Applicant: Genentech, Inc.
    Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • PRO1550 POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
    Publication number: 20090136997
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 28, 2009
    Applicant: Genentech, Inc.
    Inventors: Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
    Patent number: 7537931
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: May 26, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • PRO1303 polypeptides
    Patent number: 7538086
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: May 26, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Timothy A. Stewart, William I. Wood
  • PRO19624 antibodies
    Patent number: 7534856
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: May 19, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Protein purification
    Patent number: 7531645
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: May 12, 2009
    Assignee: Genentech, Inc.
    Inventors: Carol D. Basey, Greg S. Blank
  • THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20090118275
    Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 23, 2008
    Publication date: May 7, 2009
    Applicants: Genentech, Inc., F. Hoffmann - La Roche AG
    Inventors: Georgette M. Castanedo, Janet L. Gunzner, Kimberly Malesky, Simon Mathieu, Alan G. Olivero, Daniel P. Sutherlin, Shumei Wang, Bing-Yan Zhu, Irina Chuckowree, Adrian Folkes, Sally Oxenford, Nan Chi Wan
  • Humanized anti-beta7 antagonists and uses therefor
    Patent number: 7528236
    Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: May 5, 2009
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Mark S. Dennis
  • Humanized anti-TGF-beta antibodies
    Patent number: 7527791
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: May 5, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen H. Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • Pantropic neurothrophic factors
    Patent number: 7528233
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: May 5, 2009
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow